D-0177-2021 Class II Terminated
FDA drug recall D-0177-2021 was initiated by Imprimis NJOF, LLC on Dec 17, 2020 and is designated Class II. Reason for recall: Lack of assurance of sterility: 13 vials were discovered to have faulty crimps. The recall status is terminated (terminated Aug 23, 2023). Affected quantity: 6520 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 6, 2021
- Initiation Date
- Dec 17, 2020
- Termination Date
- Aug 23, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 6520 vials
Product description
Dexamethasone - Moxifloxacin PF Injection (1/5) mg/mL, Imprimis Rx Volume: 1mL/vial, Imprimis NJOF, LLC. 1705 Route 46 West, Unit 6B Ledgewood, NJ - 07852 (844)446-6979
Reason for recall
Lack of assurance of sterility: 13 vials were discovered to have faulty crimps.
Distribution pattern
U.S.A. Nationwide
Code information
Lot#: 20JUN010, Exp 5/12/21
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0177-2021
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026